Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03241927 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)
A Phase 2 study, sponsored by Nina Bhardwaj.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT03241927 is a Phase 2 study that was terminated before completion, run by Nina Bhardwaj. The registered enrollment target is 1 participants.
The verdict
NCT03241927, a Phase 2 study, was terminated before completion, sponsored by Nina Bhardwaj.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
Melanoma is an immune-modulated malignancy and immune checkpoint modulators which inhibit PD-1 function (pembrolizumab, nivolumab) have demonstrated clinical efficacy as treatment for patients with stage IV melanoma. Pembrolizumab across a range of doses in phase I investigation has demonstrated clinical efficacy with RR approximately 27%. By better understanding how NK cell function and exhaustion interplays with PD1 function and activity, potentially more efficacious combination therapies can be developed. The pharmacodynamic studies to be performed as part of this trial will provide such information.
Interventions
- BIOLOGICAL Pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-12-20 |
| Est. Completion | 2018-06-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03241927
The ClinicalTrials.gov registry entry for NCT03241927 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nina Bhardwaj, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT03241927 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03241927 about?
NCT03241927 is a clinical study titled "Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)". Melanoma is an immune-modulated malignancy and immune checkpoint modulators which inhibit PD-1 function (pembrolizumab, nivolumab) have demonstrated clinical efficacy as treatment for patients with stage IV melanoma. Pembrolizumab across a range of doses in phase I investigation has demonstrated cli...
What is the current status of trial NCT03241927?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2017-12-20. Estimated completion is 2018-06-06.
What interventions are being tested in trial NCT03241927?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03241927?
This trial is sponsored by Nina Bhardwaj, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.